{"id":"W2098276344","doi":"10.1016/s1470-2045(13)70335-8","title":"Adjuvant bevacizumab-containing therapy in triple-negative breast cancer (BEATRICE): primary results of a randomised, phase 3 trial","year":2013,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Breast Cancer Treatment Studies","field":"Biochemistry, Genetics and Molecular Biology","cited_by":436,"is_retracted":false,"has_abstract":false,"ca_institutions":"University of Toronto; Sunnybrook Health Science Centre","funders":"National Institute for Health and Care Research","keywords":"Medicine; Bevacizumab; Breast cancer; Internal medicine; Oncology; Anthracycline; Clinical endpoint; Taxane; Chemotherapy; Population; Triple-negative breast cancer; Ixabepilone; Cancer; Surgery; Randomized controlled trial; Metastatic breast cancer","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005658009,0.0002227532,0.0007678991,0.00005744858,0.00007277462,0.000009180809,0.0003034206,0.0001568044,0.00005912456],"category_scores_gemma":[0.0001298064,0.0001430158,0.0001275033,0.0001669888,0.0002260384,0.000008666421,0.0001111585,0.0001697132,0.000006486669],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0001579707,"about_ca_system_score_gemma":0.0003213751,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.002451502,"about_ca_topic_score_gemma":0.0007034087,"domain_scores_codex":[0.9981788,0.000453292,0.0004902897,0.0003589601,0.0001292369,0.0003893863],"domain_scores_gemma":[0.9987804,0.0002875946,0.0003502128,0.000396277,0.0001384433,0.00004702303],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.8349676,0.0008132418,0.001279634,0.00001728284,0.0005332465,0.000009893367,0.001529685,0.00003274695,0.02324295,0.00002020608,0.006147271,0.1314062],"study_design_scores_gemma":[0.9488831,0.003437987,0.03309409,0.0000348575,0.00008087514,0.00003472459,0.0004920453,0.00002368365,0.008619139,0.0002176576,0.004831149,0.0002507041],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9874249,0.002171447,0.00001546827,0.004920166,0.0003355521,0.00185878,0.0003153819,0.00001416546,0.002944166],"genre_scores_gemma":[0.993267,0.003256813,0.000169141,0.000872804,0.001015823,0.001197045,0.00007168627,0.00002051026,0.0001291897],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.1311555,"threshold_uncertainty_score":0.5832015,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.03051684271619915,"score_gpt":0.3359500223103854,"score_spread":0.3054331795941863,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}